AU2002236476A1 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
AU2002236476A1
AU2002236476A1 AU2002236476A AU3647602A AU2002236476A1 AU 2002236476 A1 AU2002236476 A1 AU 2002236476A1 AU 2002236476 A AU2002236476 A AU 2002236476A AU 3647602 A AU3647602 A AU 3647602A AU 2002236476 A1 AU2002236476 A1 AU 2002236476A1
Authority
AU
Australia
Prior art keywords
novel compounds
occurred
excessive
inappropriate
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002236476A
Other languages
English (en)
Inventor
Jerry L. Adams
Deborah L. Bryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002236476A1 publication Critical patent/AU2002236476A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
AU2002236476A 2000-11-20 2001-11-20 Novel compounds Abandoned AU2002236476A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24996300P 2000-11-20 2000-11-20
US60/249,963 2000-11-20
PCT/US2001/043814 WO2002039954A2 (en) 2000-11-20 2001-11-20 Novel compounds

Publications (1)

Publication Number Publication Date
AU2002236476A1 true AU2002236476A1 (en) 2002-05-27

Family

ID=22945749

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002236476A Abandoned AU2002236476A1 (en) 2000-11-20 2001-11-20 Novel compounds

Country Status (8)

Country Link
US (2) US20040053943A1 (de)
EP (1) EP1343779B1 (de)
JP (1) JP4217480B2 (de)
AT (1) ATE365730T1 (de)
AU (1) AU2002236476A1 (de)
DE (1) DE60129154T2 (de)
ES (1) ES2289004T3 (de)
WO (1) WO2002039954A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1529901A (en) * 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
EP1263753B1 (de) * 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivate als raf kinase inhibitoren
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
JP2005504793A (ja) * 2001-09-05 2005-02-17 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのヘテロサイクルカルボキサミド誘導体
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
CA2540518A1 (en) * 2003-10-02 2005-04-07 Irm Llc Compounds and compositions as protein kinase inhibitors
GB0402100D0 (en) * 2004-01-30 2004-03-03 Novartis Ag Organic compounds
ITMI20041279A1 (it) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
US20060173048A1 (en) * 2005-02-03 2006-08-03 Mcarthur Silvia G Imidazole derivatives
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
KR20130040258A (ko) * 2008-03-21 2013-04-23 노파르티스 아게 신규한 헤테로시클릭 화합물 및 그의 용도
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
RU2470911C2 (ru) * 2011-03-29 2012-12-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный технологический университет" (СибГТУ) Способ получения n-алкил-3-метил-4-нитрозоанилинов
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
CA2332402A1 (en) * 1998-05-22 1999-12-02 Susan B. Dillon Novel 2-alkyl substituted imidazole compounds
AU1529901A (en) * 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
AU2001287901A1 (en) * 2000-09-21 2002-04-02 Smithkline Beecham P.L.C. Imidazole derivatives as Raf kinase inhibitors

Also Published As

Publication number Publication date
EP1343779B1 (de) 2007-06-27
JP2004513901A (ja) 2004-05-13
EP1343779A2 (de) 2003-09-17
WO2002039954A3 (en) 2003-04-03
US7449484B2 (en) 2008-11-11
DE60129154D1 (de) 2007-08-09
JP4217480B2 (ja) 2009-02-04
DE60129154T2 (de) 2008-02-28
ATE365730T1 (de) 2007-07-15
EP1343779A4 (de) 2004-01-28
ES2289004T3 (es) 2008-02-01
US20040053943A1 (en) 2004-03-18
US20060166988A1 (en) 2006-07-27
WO2002039954A2 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU1529901A (en) Compounds
AU2002236476A1 (en) Novel compounds
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
BG106585A (en) Kinase inhibitors as therapeutic agents
NZ514711A (en) Compounds useful as anti-inflammatory agents
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
UA82980C2 (ru) Замещенные амиды бензойной кислоты и их применение для угнетения ангиогенеза
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
AU2002234806A1 (en) Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
AU2351095A (en) Benzimidazole derivatives having dopaminergic activity
SE0101082D0 (sv) Novel use
NZ516620A (en) 1,4-substituted 4,4-diaryl cyclohexanes
AU2002251788A1 (en) Novel compounds and uses thereof
MXPA04004980A (es) Antagonistas del receptor ccr-3.
MXPA04005176A (es) N-ureido-piperidinas como antagonistas viii para receptores ccr-3.
MXPA02002007A (es) Compuestos de bencimidazol sustituidos con alcoxi, preparaciones farmaceuticas que contienen los mismos, metodos para usarlos.
AU5868699A (en) Novel therapeutic use of compounds with beta-3-agonist activity
AU2001244537A1 (en) Use of natural compounds having antiangiogenic activity
WO2001068070A8 (en) Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
MY141461A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity